<div id="readability-page-1">CDT Equity Inc. ( CDT ) shares are trading higher on Monday as traders lean into a modestly constructive tape even while the health care sector is slipping. The Nasdaq is up 0.08% while the S&amp;P 500 has gained 0.03%. • CDT Equity ( CDT ) stock is among today’s top performers. What’s behind CDT gains? Small-caps are also slightly supportive with the Russell 2000 up 0.29%, which can help higher-volatility names stabilize after steep drawdowns. Also, the Dow is down 0.41%, reinforcing that this is a mixed session rather than a clean risk-on surge. However, last week, the company’s share took a hit after it filed for a non-timely 10K with the U.S. SEC and disclosed loss generated in 2025. <h2>Reported 2025 Net Loss</h2> Last week, the company said it expects its net loss to widen by about $21.3 million to around $39.1 million in 2025. This is mainly attributed to higher professional fees, travel costs, salaries, stock-based compensation and contingent loss accruals. Notably, CDT Equity ( CDT ) is a data-driven biopharmaceutical development company that focuses on finding and advancing therapeutic assets using scientific innovation and strategic partnerships. Its platform leans on artificial intelligence, solid-form chemistry, and asset repositioning to move potential treatments forward more efficiently. CDT Equity ( CDT ) is set to report earnings on April 24 (estimated). <h2>Technical Analysis</h2> At $4, CDT Equity ( CDT ) is trading 49.1% below its 20-day simple moving average (SMA), the stock's average price over the last 20 sessions, which suggests the near-term trend is still pointed down. It's also trading 84.6% below its 100-day SMA, indicating the intermediate trend remains heavily pressured. The relative strength index (RSI), a momentum gauge, is 28.39 after entering oversold territory on 2026-04-10, which suggests selling pressure has been extreme and may be tiring. That said, oversold readings can persist when the broader trend is weak. Over the last 12 months, the stock is down 99.83%, a backward-looking read that highlights how dominant the longer-term downtrend has been. CDT is also sitting near the bottom of its 52-week range (low $3.64 vs. high $4200), which is consistent with a market still treating rallies as fragile. <ul> <li>Key Resistance: $8.50 — near the 20-day average area where rebounds can stall.</li> <li>Key Support: $3.50 — a floor trader watches for demand to show up.</li> </ul> <h2>Sector Performance</h2> CDT Equity ( CDT ) is outperforming its health care sector today, up 1.96% versus State Street Health Care Select Sector ETF , down 0.23%, a gap of 2.19 percentage points that signals stock-specific buying interest. That relative strength matters because it's happening while the sector is in the red and sitting mid-pack at six out of 11 sectors. Health care has been trending lower, down 2.63% over the past 30 days and down 6.19% over the past 90 days, which can cap follow-through on bounces. With technology leading today at +0.69% and health care lagging, CDT Equity’s move is less about sector tailwinds and more about traders probing for a bottom after the recent slide. <h2>Benzinga Edge Rankings</h2> Below is the Benzinga Edge scorecard for CDT Equity ( CDT ), highlighting its strengths and weaknesses compared to the broader market: <ul> <li>Momentum: Weak (Score: 0.11) — The trend profile is extremely bearish versus the broader market.</li> </ul> The Verdict: CDT Equity’s Benzinga Edge signal reveals weakness across key pillars, with the only available datapoint (momentum) flagging severe underperformance. Until momentum improves materially, rallies may continue to face quick profit-taking and failed follow-through risk. CDT Stock Price Activity: CDT Equity ( CDT ) shares were up 14.71% at $4.68 at the time of publication on Monday, according to Benzinga Pro data. Photo via Shutterstock </div>

CDT Equity Inc. shares are rising ahead of earnings, recovering from a decline due to a delayed SEC filing and expectations of wider net losses. The stock is trading at $4.68, up 14.71%, but remains significantly below its moving averages, indicating a bearish trend. The company expects a net loss of $39.1 million in 2025, attributed to increased costs. Despite the health care sector's overall decline, CDT is outperforming, suggesting specific buying interest as traders look for a bottom after recent losses. Earnings are expected to be reported on April 24.

Fidelity

CDT Equity

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares Global Healthcare

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VG Health

iShares US Pharma

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

What's Going On With CDT Equity Shares On Monday?